You simply do not obsess over it
This decision is based on the strong obesity data obtained for semaglutide and AM833 that, in aggregate, have raised the innovation bar for future Novo Nordisk obesity care and we've, therefore, prioritized our resources accordingly to achieve the best possible patient outcomes and product benefit risk profile
On iOS and Android
The proposal would allow the agency to classify drugs as misbranded if ads exaggerate effectiveness, fail to disclose key risks, or mislead consumers, and would impose stricter rules on compounded drugs that are not FDA-approved
The ongoing Phase 3 programme known as the TRIUMPH trials is evaluating retatrutide across a broader population, including individuals with obesity, type 2 diabetes, and cardiovascular risk factors
J Clin Endocrinol Metab (2020) 105:295063